Organon (OGN) Other Working Capital Changes (2020 - 2026)
Organon (OGN) recorded quarterly Other Working Capital Changes of -$8.0 million in Q1 2026, up 20.0% quarter-over-quarter from -$10.0 million in Q4 2025, and down 172.73% on a YoY basis from $11.0 million in Q1 2025.
Organon (OGN) Other Working Capital Changes (2020 - 2026) Analysis & Trends
Organon's Other Working Capital Changes history runs 7 years deep, the most recent figure standing at -$8.0 million for Q1 2026.
- In Q1 2026, Other Working Capital Changes fell 172.73% year-over-year to -$8.0 million; the TTM figure through Mar 2026 stood at -$158.0 million (down 4050.0% YoY), while the FY2025 annual figure was -$139.0 million, down 379.31% from the prior year.
- Other Working Capital Changes was -$8.0 million for Q1 2026 at Organon, up from -$10.0 million in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $178.0 million in Q2 2024 to a low of -$223.0 million in Q3 2024.
- Historically, Other Working Capital Changes has averaged -$11.5 million across 5 years, with a median of -$8.0 million in 2025.
- Biggest YoY gain for Other Working Capital Changes was 584.62% in 2024; the steepest drop was 555.1% in 2024.
- A 5-year view of Other Working Capital Changes shows it stood at $16.0 million in 2022, then slumped by 550.0% to -$72.0 million in 2023, then jumped by 152.78% to $38.0 million in 2024, then plunged by 126.32% to -$10.0 million in 2025, then gained by 20.0% to -$8.0 million in 2026.
- The last three Other Working Capital Changes figures came in at -$8.0 million (Q1 2026), -$10.0 million (Q4 2025), and -$8.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,134,969.93 Bn | 92,134,964.97 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,027.45 Bn | 1,022.17 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 559.08 Bn | 537.03 Bn | 15.96 Bn |
| 4 | AbbVie | 394.75 Bn | 385.40 Bn | 10.78 Bn |
| 5 | Merck | 295.12 Bn | 289.47 Bn | 12.09 Bn |
| 6 | Amgen | 186.65 Bn | 174.61 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 159.22 Bn | 151.50 Bn | 5.52 Bn |
| 8 | Pfizer | 146.00 Bn | 133.23 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 113.22 Bn | 102.77 Bn | 8.07 Bn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.00 Mn |
| Mar 31, 2026 | -8.00 Mn |
| Dec 31, 2025 | -10.00 Mn |
| Dec 31, 2025 | -10.00 Mn |
| Sep 30, 2025 | -8.00 Mn |
| Sep 30, 2025 | -8.00 Mn |
| Jun 30, 2025 | -132.00 Mn |
| Jun 30, 2025 | -132.00 Mn |
| Mar 31, 2025 | 11.00 Mn |
| Mar 31, 2025 | 11.00 Mn |
| Dec 31, 2024 | 38.00 Mn |
| Dec 31, 2024 | 38.00 Mn |
| Sep 30, 2024 | -223.00 Mn |
| Sep 30, 2024 | -223.00 Mn |
| Jun 30, 2024 | 178.00 Mn |
| Jun 30, 2024 | 178.00 Mn |
| Mar 31, 2024 | -22.00 Mn |
| Mar 31, 2024 | -22.00 Mn |
| Dec 31, 2023 | -72.00 Mn |
| Dec 31, 2023 | -72.00 Mn |